Skip to main content
Figure 4 | Molecular Cancer

Figure 4

From: Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma

Figure 4

Inhibition of WEE1 by the small molecule inhibitor MK-1775. (A) A decrease in relative cell number was seen by MTS assay through a wide range of MK-1775 concentrations in both Daoy and UW228 cells. From this data the IC50 values were calculated. (B) Treatment with an IC30 of MK-1775 for 48 hours significantly decreased the relative colony numbers in Daoy and UW228 cells. Shown are representative images from each treatment group with the quantifying bar graph for each cell line below the images. (C) Exposure to increasing concentrations of MK-1775 in Daoy and UW228 cells showed a dose dependent decrease in WEE1 activity as seen by decreased phospho-CDK1 (Tyr15). There was no significant change in WEE1 levels. (D) Treatment with MK-1775 is sufficient to decrease subcutaneous tumor growth of Daoy cells in mice. Mice were treated on three consecutive days a week for the first three weeks after tumor establishment.

Back to article page